The study has also shown that Danshensu has been demonstrated to improve NSCLC cells’ radiosensitivity; consequently, patients with lung cancer may benefit from MAO-B inhibitors or MAO-B-activated prodrugs [4]. This evidence concerns the gene MAOB and non-small cell lung carcinoma.